220 related articles for article (PubMed ID: 34588156)
1. Viral-like Reaction or Hypersensitivity? Erythema Multiforme Minor Reaction and Moderate Eosinophilia After the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 Vaccine.
de Las Vecillas L; López J; Morchón E; Rodriguez F; Drake M; Martino M
J Investig Allergol Clin Immunol; 2021 Feb; 32(1):77-78. PubMed ID: 34588156
[No Abstract] [Full Text] [Related]
2. [Erythema multiforme following COVID-19 vaccination (BNT162b2)].
Wunderlich K; Dirschka T
Hautarzt; 2022 Jan; 73(1):68-70. PubMed ID: 34676438
[TBL] [Abstract][Full Text] [Related]
3. Atypical erythema multiforme related to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.
Buján Bonino C; Moreiras Arias N; López-Pardo Rico M; Pita da Veiga Seijo G; Rosón López E; Suárez Peñaranda JM; Sánchez-Aguilar Rojas D
Int J Dermatol; 2021 Nov; 60(11):e466-e467. PubMed ID: 34473839
[No Abstract] [Full Text] [Related]
4. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.
Lavery MJ; Nawimana S; Parslew R; Stewart L
Clin Exp Dermatol; 2021 Oct; 46(7):1325-1327. PubMed ID: 33914926
[No Abstract] [Full Text] [Related]
5. Pfizer-BioNTech SARS-CoV-2 mRNA vaccine-associated erythema multiforme.
Borg L; Mercieca L; Mintoff D; Micallef D; Pisani D; Betts A; Scerri L
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e22-e24. PubMed ID: 34547125
[No Abstract] [Full Text] [Related]
6. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases.
Petruzzi M; Galleggiante S; Messina S; Della Vella F
BMC Oral Health; 2022 Mar; 22(1):90. PubMed ID: 35331228
[TBL] [Abstract][Full Text] [Related]
7. Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty
Ando M; Satonaga Y; Takaki R; Yabe M; Kan T; Omote E; Yamasaki T; Komiya K; Hiramatsu K
Int J Infect Dis; 2022 Nov; 124():187-189. PubMed ID: 36122668
[TBL] [Abstract][Full Text] [Related]
8. Generalized erythema multiforme-like skin rash following the first dose of COVID-19 vaccine (Pfizer-BioNTech).
Kim MJ; Kim JW; Kim MS; Choi SY; Na JI
J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):e98-e100. PubMed ID: 34661942
[No Abstract] [Full Text] [Related]
9. Non-episodic angioedema with eosinophilia after BNT162b2 mRNA COVID-19 vaccination.
Ishizuka K; Katayama K; Kaji Y; Tawara J; Ohira Y
QJM; 2021 Dec; 114(10):745-746. PubMed ID: 34546346
[No Abstract] [Full Text] [Related]
10. Eosinophilic cellulitis after BNT162b2 mRNA Covid-19 vaccine.
de Montjoye L; Marot L; Baeck M
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e26-e28. PubMed ID: 34547138
[No Abstract] [Full Text] [Related]
11. Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination.
Gambichler T; Scholl L; Dickel H; Ocker L; Stranzenbach R
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e415-e416. PubMed ID: 33725406
[No Abstract] [Full Text] [Related]
12. A definite case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by administration of the Pfizer/BioNTech BNT162b2 vaccine for SARS-CoV2.
Schroeder JW; Gamba C; Toniato A; ; Rongioletti F
Clin Dermatol; 2022; 40(5):591-594. PubMed ID: 35550918
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months.
Ponticelli D; Antonazzo IC; Caci G; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P
J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34697627
[No Abstract] [Full Text] [Related]
14. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 mRNA Vaccine-induced Pneumonitis.
Matsuzaki S; Kamiya H; Inoshima I; Hirasawa Y; Tago O; Arai M
Intern Med; 2022 Jan; 61(1):81-86. PubMed ID: 34707048
[TBL] [Abstract][Full Text] [Related]
16. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
17. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
19. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
[TBL] [Abstract][Full Text] [Related]
20. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine.
Sechi A; Pierobon E; Pezzolo E; Germi L; Trevisan G; Zardo D; Riva G; Mondino S; Naldi L
Clin Exp Dermatol; 2022 Feb; 47(2):437-440. PubMed ID: 34617317
[No Abstract] [Full Text] [Related]
[Next] [New Search]
